The plateau is in the trial curves. Here is what the data says to do about it.
Around month 9 to 12, nearly every GLP-1 weight curve flattens — including in the trials that made these drugs famous. What happens next is a decision, not a malfunction.
Plateaus on GLP-1s are near-universal and visible in every pivotal trial: STEP-1 weight loss flattened around weeks 60–68 at about 15 percent, SURMOUNT-1 around weeks 60–72 at 20+ percent. The plateau reflects metabolic adaptation and a new energy equilibrium, not drug failure. Evidence-supported responses, in order: verify dose and adherence, address diet drift, escalate dose if not at maximum, and — per SURMOUNT-5 — consider switching semaglutide to tirzepatide, which averaged 6 points more total loss head-to-head.
- The plateau is in the published curves: Look at the weight-change graphs in the pivotal papers and the story is identical everywhere: steep loss for six months, a slowing slope through mo....
- Before changing anything: First, dose reality.
- Dose escalation: If you plateaued below goal and are not at maximum dose, escalation is the on-label move: semaglutide's treatment dose is 2.4 mg weekly, tirzepatid....
- Switching drugs: The first large head-to-head, SURMOUNT-5, randomized adults with obesity to tirzepatide or semaglutide at treatment doses: tirzepatide averaged abo....
- The non-drug levers with trial support: Resistance training and protein sufficiency — covered in depth in our muscle-loss article — do double duty at a plateau: they protect lean mass and....
The plateau is in the published curves
Look at the weight-change graphs in the pivotal papers and the story is identical everywhere: steep loss for six months, a slowing slope through month nine, then a flat line that continues as long as treatment does. STEP-1's semaglutide arm flattened near 15 percent total loss; SURMOUNT-1's top tirzepatide dose flattened around 21 percent. The flat line is not the drug quitting — participants who stayed on therapy maintained the loss for the full trial duration.
A plateau is your body reaching equilibrium: a smaller body burns fewer calories, appetite-suppression effects meet a new baseline intake, and the deficit that produced loss closes. Every successful weight-loss method known produces this curve. The question is only whether your plateau sits at your goal or short of it.
| Trial | Drug / dose | Plateau begins | Plateau level |
|---|---|---|---|
| STEP-1 | Semaglutide 2.4 mg | ~wk 60 | ~−15% |
| SURMOUNT-1 | Tirzepatide 15 mg | ~wk 60–72 | ~−21% |
| SURMOUNT-5 | Tirzepatide vs sema | ~wk 60+ | −20% vs −14% |
| OASIS 4 | Oral sema 25 mg | ~wk 52–64 | ~−14 to −17% |
Before changing anything: the three boring checks
First, dose reality. A large share of “plateaued” patients on compounded or vial-based products are under-dosing — drawing errors, skipped weeks during refill gaps, or programs that cap doses below therapeutic levels (see our dose-cap warning article). Confirm the milligrams you are actually injecting against your prescription.
Second, intake drift. Appetite suppression fades between doses and adapts over months; food logs in plateau studies routinely show intake creeping several hundred calories above the loss-phase level without the patient noticing. A two-week honest log outperforms any medication change as a first diagnostic. Third, timeline honesty: a flat month after nine months of loss is the expected curve, not a plateau requiring intervention.
Dose escalation: the labeled next step
If you plateaued below goal and are not at maximum dose, escalation is the on-label move: semaglutide's treatment dose is 2.4 mg weekly, tirzepatide's range runs to 15 mg. The trials embedded this logic — their results came from full titration schedules, and stopping escalation early predictably produces earlier, higher plateaus.
The cost dimension is real and is where our pricing work bites: on programs that charge by dose, moving from a mid to top dose can add $100–$200 per month, while flat-priced programs charge nothing extra. If a dose increase is clinically indicated but your program's pricing punishes it, our price-by-dose breakdown lists the programs where escalation is free.
Switching drugs: what SURMOUNT-5 licenses
The first large head-to-head, SURMOUNT-5, randomized adults with obesity to tirzepatide or semaglutide at treatment doses: tirzepatide averaged about 20 percent loss versus roughly 14 percent for semaglutide at 72 weeks. For a patient plateaued on maximal semaglutide short of goal, a supervised switch to tirzepatide is the single best-evidenced pharmacologic move available in 2026.
Switches require re-titration — you do not jump to the equivalent-feeling dose — and insurance or program pricing may differ between molecules. The reverse switch (tirzepatide to semaglutide) has no efficacy rationale and is usually driven by cost or availability; the oral options (Wegovy pill, Foundayo) add convenience-motivated switch paths with their own trade-offs.
The non-drug levers with trial support
Resistance training and protein sufficiency — covered in depth in our muscle-loss article — do double duty at a plateau: they protect lean mass and raise resting energy expenditure, directly attacking the adaptation that created the plateau. Sleep and alcohol are the two quiet saboteurs; short sleep reliably raises intake in controlled studies, and alcohol both adds calories and blunts satiety signaling.
What does not have evidence: “drug holidays” to reset receptor sensitivity (no trial supports this, and discontinuation trials show regain, not resensitization), aggressive further calorie cutting below roughly 1,200 kcal (accelerates lean loss), and stacking unregulated peptides on top of therapy.
If the plateau is at goal: that is maintenance
A plateau at or near your target weight is the treatment working. The open clinical question of 2026 is maintenance strategy: continued full dose, reduced dose, spacing injections, or transition to an oral. Discontinuation data is sobering — in withdrawal studies, participants regained roughly two-thirds of lost weight within a year of stopping — so “plateaued, therefore done” is the costliest misreading of the curve.
Maintenance-dose economics favor flat-priced programs and, from 2027, Medicare's negotiated semaglutide price for eligible beneficiaries. Whatever the plan, it should be a plan — the default of drifting off therapy has the worst-documented outcomes of any option on this page.
Frequently asked questions
How long should weight loss last before a plateau is normal?
Trial curves show steady loss for roughly 6–9 months, slowing into a flat line by 12–18 months. A flat few weeks mid-course is noise; a flat quarter at month 10 is the expected physiology.
Should I take a break from the drug to reset it?
No evidence supports drug holidays for resensitization, and withdrawal studies show substantial regain. If you are plateaued short of goal, dose, drug choice and intake drift are the evidence-backed levers.
Will switching to tirzepatide break my semaglutide plateau?
SURMOUNT-5 showed about 6 percentage points more average loss with tirzepatide head-to-head, making a supervised switch the best-evidenced pharmacologic option for a maxed-out semaglutide plateau short of goal.